Isfahan

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

Dystrophic Epidermolysis Bullosa (DEB) is a genetic skin disorder causing fragile skin that blisters and bleeds easily, sometimes leading to severe complications and increased risk of skin cancer. This study investigates the use of Ev.FV, a biological treatment derived from mesenchymal stem cell extracellular vesicles containing five key factors, as a new method to promote wound healing and skin regeneration in patients with DEB. The trial is a Phase 1 and 2 randomized clinical study evaluating the safety and effectiveness of this treatment. Ev.FV will be administered intravenously at a dose of 1.0 x 10^11 particles per milliliter, given in a total of six doses every two weeks. These extracellular vesicles work by transferring important biomolecules to skin cells, helping modulate inflammation, stimulate skin cell growth, promote new blood vessel formation, and support repair of skin adhesion structures. This cell-free approach aims to provide a safer and more controlled alternative to stem cell transplantation for treating DEB. Participants with DEB who have active wounds will receive the treatment and be closely monitored over time. Researchers will assess wound closure rates by day 14 and measure disease severity using a scoring index at days 14, 28, and months 3 and 6. The study involves regular evaluations, including safety monitoring, and aims to understand how well this new therapy aids wound healing and skin regeneration in this challenging condition.

This research investigates the effectiveness of adding an oral curcumin treatment to intravitreal bevacizumab injections in patients with diabetic macular edema. It is a randomized, controlled, and blinded clinical trial focusing on patients with central macular edema related to diabetes. The primary goals are to measure changes in central macular thickness and volume, with a secondary focus on evaluating the best visual acuity of participants. Participants receive intravitreal injections of bevacizumab at a standard dose of 1.25 mg/0.05 ml, administered three times at one-month intervals. The study compares two groups: one receiving oral curcumin tablets twice daily at 40 mg for three months alongside bevacizumab, and a control group receiving placebo tablets twice daily for the same duration along with bevacizumab injections. During the three-month study period, participants undergo evaluations of their macular thickness and volume, as well as visual acuity assessments. Researchers monitor these outcomes to determine treatment effects. Safety and adherence are observed throughout the study, which lasts for at least three months from the start of treatment.

This research investigates the use of exosomes derived from mesenchymal stem cells (MSCs) as a potential treatment for knee osteoarthritis (OA), a condition marked by cartilage damage and joint inflammation. OA involves increased activity of enzymes and inflammatory molecules that degrade joint tissue. MSCs have been studied for their ability to help repair joint damage, and exosomes are thought to play a key role in this process by carrying beneficial molecules that can reduce inflammation and support cell function within the joint. The study involves administering exosomes through injections directly into the knee joint twice: once on day 1 and again on day 90. These small vesicles carry proteins and non-coding RNAs from MSCs that may help modulate the joint environment and potentially suppress OA progression. The treatment is biological and targets the joint locally. Participants will be monitored over six months, with assessments including the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) at 1, 3, and 6 months after the first injection. The trial aims to evaluate the effects of the exosome injections on OA symptoms and joint function. Safety and response to treatment will be closely observed throughout the study period.

Researchers are studying how individual and societal factors affect health outcomes such as death and the development of chronic diseases across different socioeconomic and healthcare settings. This research also explores genetic influences on non-communicable diseases through both a cross-sectional and a long-term follow-up approach. The study focuses on understanding the impact of the built environment, food and nutrition policies, psychosocial and socioeconomic factors, tobacco use, and the quality of health systems. The study does not involve specific interventions but observes health-related behaviors including diet, physical activity, smoking, and alcohol use. It monitors how societal influences relate to risk factors and the occurrence of chronic diseases like cardiovascular disease and cancer. Genetic factors for non-communicable diseases are also investigated as part of this comprehensive analysis. Participants aged 35 to 70 are followed over an average of 10 years to assess the development of cardiovascular disease and other health outcomes. Researchers collect data on societal determinants, risk factors, and health behaviors, as well as genetic information. The study aims to understand how these elements relate to disease incidence and mortality, considering different health resource settings worldwide.

The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight? 2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight? In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)

Researchers are evaluating the effects of astaxanthin supplementation in women with Polycystic Ovary Syndrome (PCOS), a common endocrine disorder affecting reproductive-aged women and linked to symptoms like infertility, metabolic dysfunction, and depression. This Phase 1 randomized, double-blind, placebo-controlled trial aims to study the impact of 12 weeks of daily 10 mg astaxanthin on insulin sensitivity, lipid profile, oxidative stress markers, hirsutism severity, and depression among women with PCOS and a body mass index between 25 and 35 kg/m2. Participants will be randomly assigned to receive either a daily 10 mg astaxanthin capsule or a placebo capsule containing corn starch for 12 weeks. The study is conducted at a gynecologist clinic in Isfahan, Iran. To ensure adherence, supplement packs will be returned and counted every two weeks, and daily compliance will be monitored via social networks. Participants are instructed to maintain their usual diet and physical activity during the study. Throughout the study, participants will undergo multiple assessments including blood pressure measurements, evaluation of hirsutism severity, biochemical blood tests, dietary intake recalls, and physical activity questionnaires at baseline, 4 weeks, 8 weeks, and at study end. Blood samples for lipid profiles, insulin resistance, and oxidative stress markers will be collected fasting at the start and end of the intervention. The primary outcomes measured are changes in blood pressure, hirsutism severity, biochemical indicators, physical activity, and dietary intake across the 8-week treatment period.

Keratoconus is an eye disease that causes the cornea to become thin and distorted, often affecting both eyes unevenly. It typically begins in young people and can lead to serious vision problems. This research aims to find out how common keratoconus is among children and adolescents worldwide using modern imaging techniques, as it is believed to be more frequent than previously reported. Participants will visit the ophthalmology department once, where a special imaging test called Pentacam HR will be used to scan both eyes. This procedure takes about 15 minutes and creates a detailed 3D model of the front part of the eye. During the visit, parents or guardians will also complete a questionnaire about risk factors and confirm consent for participation. The study includes children and adolescents aged 6 to 23 years from multiple cities across North America, South America, Asia, and Europe. Throughout the study, researchers will measure how many participants have keratoconus using the imaging results. This one-time assessment will help improve understanding of the disease's frequency in young people. The study focuses on those attending medical visits for reasons unrelated to eye problems and who do not show symptoms of keratoconus. Safety and proper consent are ensured by involving parents or legal guardians during the visit.